Product Overview
[Drug Name]
Generic Name: Irbesartan Capsules
Trade Name: Yitaiqing Irbesartan Capsules 75mg*14 Capsules
Pinyin Full Code: RunDuEBeiShaTanJiaoNang 75mg*14Li
[Main Ingredient]
Irbesartan. Chemical Name: 2-Butyl-3-4-2-(1H-tetrazol-5-yl)phenylbenzyl-1,3-diazaspiro-4,4-non-1-en-4-one. Molecular Formula: C₂₅H₂₅N₂O. Molecular Weight: 428.54
[Properties]
This product is a white or off-white powder or granules.
[Indications/Main Functions]
Hypertension.
[Specifications]
75mg*14 Capsules (Yitaqing)
[Dosage and Administration]
Oral. The recommended starting dose is two capsules (0.15g) once daily. The dose can be increased to four capsules (0.3g) once daily depending on the condition. For severe hypertension and when blood pressure remains unsatisfactory after increasing the dose, a low-dose diuretic (such as a thiazide) or other antihypertensive medication may be added.
[Adverse Reactions]
Common adverse reactions include headache, dizziness, palpitations, and occasional cough. These are generally mild and transient, and most patients tolerate continued medication well. Urticaria and angioedema are rare. Literature reports of adverse reactions with an incidence greater than 1% for this product include: dyspepsia, heartburn, diarrhea, musculoskeletal pain, fatigue, and upper respiratory tract infection, but these reactions were not significantly different from the control group. Adverse reactions with an incidence greater than 1% but lower than the control group include: abdominal pain, anxiety, nervousness, chest pain, pharyngitis, nausea and vomiting, rash, and tachycardia. The incidence of hypotension and orthostatic hypotension is approximately 0.4%.
[Contraindications]
This product is contraindicated in patients with allergies.
[Drug Interactions] This product has no significant interactions with hydrochlorothiazide, digoxin, warfarin, or nifedipine. However, when used with diuretics, caution should be exercised regarding hypovolemia or the potential for hypotension due to hyponatremia. Elevated serum potassium levels should be avoided when used with potassium-sparing diuretics (such as triamterene). Concomitant use with digitalis drugs such as digoxin, beta-blockers such as atenolol, and calcium antagonists such as nifedipine does not affect the pharmacokinetics of these drugs.
[Precautions]
1. Correct hypovolemia and/or sodium depletion before initiating treatment. 2. Patients with renal insufficiency may require a dose reduction. Changes in blood urea nitrogen, serum creatinine, and potassium should also be monitored. As a result of renin-angiotensin-aldosterone inhibition, some sensitive patients may experience changes in renal function. 3. No dose adjustment is required for patients with mild to moderate hepatic impairment. 4. Irbesartan cannot be excreted through hemodialysis.
[Pediatric Use]
No safety data are available for patients under 18 years of age.
[Elderly Use]
No dosage adjustment is required for elderly patients.
[Overdose]
Overdose with this drug may cause hypotension, tachycardia, or bradycardia. Induce vomiting, gastric lavage, and supportive care should be used.
[Pharmacology and Toxicology]
This drug is an angiotensin II (AngI) receptor inhibitor that inhibits the conversion of Angl to Angl. It specifically inhibits the angiotensin-converting enzyme 1 (AT1) receptor, with a sustained inhibitory effect greater than 28,500 times that of the AT1 receptor. By selectively blocking the binding of Angl to the AT1 receptor, it inhibits vasoconstriction and aldosterone release, resulting in a hypotensive effect. This drug does not inhibit angiotensin-converting enzyme (ACE), renin, or other hormone receptors, nor does it inhibit ion channels involved in blood pressure regulation and sodium homeostasis.
